JP2009544688A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544688A5 JP2009544688A5 JP2009521380A JP2009521380A JP2009544688A5 JP 2009544688 A5 JP2009544688 A5 JP 2009544688A5 JP 2009521380 A JP2009521380 A JP 2009521380A JP 2009521380 A JP2009521380 A JP 2009521380A JP 2009544688 A5 JP2009544688 A5 JP 2009544688A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- fusion polypeptide
- phospholipase
- ptd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims 28
- 230000004927 fusion Effects 0.000 claims 19
- 238000000034 method Methods 0.000 claims 18
- 102000014384 Type C Phospholipases Human genes 0.000 claims 9
- 108010079194 Type C Phospholipases Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 230000026683 transduction Effects 0.000 claims 8
- 238000010361 transduction Methods 0.000 claims 8
- 206010021143 Hypoxia Diseases 0.000 claims 6
- 230000007954 hypoxia Effects 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000010410 reperfusion Effects 0.000 claims 5
- 230000000747 cardiac effect Effects 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 102000005701 Calcium-Binding Proteins Human genes 0.000 claims 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000021479 Cardiovascular injury Diseases 0.000 claims 2
- 102000018890 Phospholipase C delta Human genes 0.000 claims 2
- 108010013144 Phospholipase C delta Proteins 0.000 claims 2
- 230000001964 calcium overload Effects 0.000 claims 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 208000013875 Heart injury Diseases 0.000 claims 1
- 206010021113 Hypothermia Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 210000002072 atrial myocyte Anatomy 0.000 claims 1
- 230000003683 cardiac damage Effects 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 238000002586 coronary angiography Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims 1
- 230000002631 hypothermal effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000004457 myocytus nodalis Anatomy 0.000 claims 1
- 210000000651 myofibroblast Anatomy 0.000 claims 1
- 231100000878 neurological injury Toxicity 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000007556 vascular defect Effects 0.000 claims 1
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83258406P | 2006-07-24 | 2006-07-24 | |
| PCT/IB2007/003404 WO2008015580A2 (en) | 2006-07-24 | 2007-07-19 | Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544688A JP2009544688A (ja) | 2009-12-17 |
| JP2009544688A5 true JP2009544688A5 (enExample) | 2010-08-05 |
Family
ID=38997534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009521380A Pending JP2009544688A (ja) | 2006-07-24 | 2007-07-19 | 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7902154B2 (enExample) |
| EP (1) | EP2044108A4 (enExample) |
| JP (1) | JP2009544688A (enExample) |
| KR (1) | KR101574630B1 (enExample) |
| CN (1) | CN101490080A (enExample) |
| WO (1) | WO2008015580A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9416383B2 (en) * | 2007-04-27 | 2016-08-16 | University Of North Carolina At Chapel Hill | Method for enhancing catalytic activity of a lipase |
| US7981446B2 (en) * | 2007-11-26 | 2011-07-19 | Forhumantech. Co., Ltd. | Pharmaceutical compositions and methods for delivering nucleic acids into cells |
| CN101612384B (zh) * | 2009-07-23 | 2012-06-20 | 中国人民解放军第二军医大学 | 多肽小分子mlif在制备防治心肌缺血药物中的应用 |
| KR101278221B1 (ko) * | 2010-06-01 | 2013-06-24 | 연세대학교 산학협력단 | Ρtd-uqcrb 융합 폴리펩타이드 및 그를 포함하는 허혈성 질환의 예방 및 치료용 약제학적 조성물 |
| KR101873773B1 (ko) | 2012-05-11 | 2018-08-02 | 주식회사 젬백스앤카엘 | 류마티즘 관절염 예방 또는 치료 조성물 |
| CN108841802B (zh) | 2012-05-11 | 2023-06-09 | 珍白斯凯尔有限公司 | 抗炎性肽及包含其的组合物 |
| JP6272853B2 (ja) | 2012-07-11 | 2018-01-31 | ジェムバックス アンド カエル カンパニー,リミティド | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| WO2014171792A1 (ko) | 2013-04-19 | 2014-10-23 | 주식회사 카엘젬백스 | 허혈성 손상 치료 및 예방용 조성물 |
| EP4063863A1 (en) | 2013-06-07 | 2022-09-28 | Gemvax & Kael Co., Ltd. | Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients |
| CN105324123B (zh) | 2013-06-21 | 2022-02-08 | 珍白斯凯尔有限公司 | 激素分泌调节剂、包含该调节剂的组合物、和利用其控制激素分泌的方法 |
| EP3072519B1 (en) | 2013-11-22 | 2020-08-19 | Gemvax & Kael Co., Ltd. | Peptide having angiogenesis inhibitory activity and composition containing same |
| US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
| ES2908096T3 (es) | 2014-04-11 | 2022-04-27 | Gemvax & Kael Co Ltd | Péptido con actividad inhibidora de la fibrosis y composición que lo contiene |
| WO2015170790A1 (ko) * | 2014-05-09 | 2015-11-12 | 주식회사 카엘젬백스 | 허혈성 손상 치료 및 예방용 조성물 |
| WO2015167067A1 (ko) * | 2014-04-30 | 2015-11-05 | 주식회사 카엘젬백스 | 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| CN107405380B (zh) | 2015-02-27 | 2021-04-20 | 珍白斯凯尔有限公司 | 用于预防听觉损伤的肽及其包含该肽的组合物 |
| JP6923453B2 (ja) | 2015-07-02 | 2021-08-18 | ジェムバックス アンド カエル カンパニー,リミティド | 抗ウイルス活性効能を有するペプチド及びこれを含む組成物 |
| WO2017176087A1 (ko) | 2016-04-07 | 2017-10-12 | 주식회사 젬백스앤카엘 | 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| KR20250057224A (ko) | 2023-10-19 | 2025-04-29 | 단국대학교 천안캠퍼스 산학협력단 | Pdrn을 이용한 유치줄기세포를 포함하는 세포치료제 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6166191A (en) * | 1996-08-23 | 2000-12-26 | Chiron Corporation | Human polyhomeotic 1(HPH1) acts as an oncogene |
| US20030104622A1 (en) * | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
| GB0103110D0 (en) * | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
| KR20030062788A (ko) * | 2002-01-19 | 2003-07-28 | 포휴먼텍(주) | 생체분자 전달 펩타이드 mph1-btm 및 이것을포함하는 생명공학제품 |
| KR20030062789A (ko) | 2002-01-19 | 2003-07-28 | 포휴먼텍(주) | 생체분자 전달 펩타이드 sim2-btm 및 이것을포함하는 생명공학제품 |
| KR100591936B1 (ko) | 2002-11-12 | 2006-06-22 | 포휴먼텍(주) | 세포내 dna/rna 전달 방법, 및 이것의 기초 및임상학적 응용 |
| US7166692B2 (en) * | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
| ZA200509229B (en) * | 2003-05-01 | 2007-03-28 | Cornell Res Foundation Inc | Method and carrier complexes for delivering molecules to cells |
| WO2004113497A2 (en) * | 2003-06-09 | 2004-12-29 | University Of Florida | Gene delivery to tumors |
| US7723299B2 (en) * | 2005-11-04 | 2010-05-25 | Forhumantech. Co., Ltd. | Methods for treating rheumatoid arthritis using a CTLA-4 fusion protein |
| US20080132450A1 (en) * | 2006-08-29 | 2008-06-05 | Forhumantech. Co., Ltd. | Pharmaceutical composition for suppression of apoptosis and method for delivering the same |
-
2007
- 2007-07-19 CN CNA2007800276518A patent/CN101490080A/zh active Pending
- 2007-07-19 WO PCT/IB2007/003404 patent/WO2008015580A2/en not_active Ceased
- 2007-07-19 JP JP2009521380A patent/JP2009544688A/ja active Pending
- 2007-07-19 KR KR1020097001545A patent/KR101574630B1/ko not_active Expired - Fee Related
- 2007-07-19 EP EP07825623A patent/EP2044108A4/en not_active Withdrawn
- 2007-07-24 US US11/878,431 patent/US7902154B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544688A5 (enExample) | ||
| TWI480069B (zh) | 用以改善心肌梗塞之醫藥組成物 | |
| RU2582247C2 (ru) | Ингибиторы апоптоза и их применение | |
| ES2632553T3 (es) | Novedosos agonistas de receptor tipo 2 de angiotensina (AT2) y sus usos | |
| JP2022520193A (ja) | Cnpコンジュゲートの乾燥医薬製剤 | |
| CN110114065A (zh) | 通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生 | |
| HUP0303763A2 (hu) | A trombinnal aktiválható fibrinolízist gátló (TAFIa-gátló) szubsztituált imidazolok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| JP2012518636A (ja) | 神経ペプチドy受容体結合化合物を有する細胞毒性コンジュゲート | |
| WO2016118577A1 (en) | Thymosin-beta-four fusion proteins | |
| US11370816B2 (en) | Histatins and method of use thereof | |
| WO2007009359A1 (en) | Thymosin beta 4 derivatives and use thereof | |
| KR101746749B1 (ko) | 뇌졸중-유발된 혈관신생 증진제 및 이의 용도 | |
| EA201791668A1 (ru) | Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада | |
| US20160168210A1 (en) | Derivatives of collagen-binding hairpin peptides | |
| JP2025521751A (ja) | コラーゲンペプチドベースの医薬組成物及びその使用 | |
| CN106063928B (zh) | 一种多肽或其衍生物在治疗高血压性心肌肥厚中的应用 | |
| JP2006516287A (ja) | Mntfペプチドおよび組成物ならびに使用の方法 | |
| WO2019106680A1 (en) | Treatment of an ischemic heart disease | |
| KR20190050277A (ko) | 허혈성 심혈관 질환의 치료용 또는 예방용 약학 조성물 | |
| CN112390877B (zh) | Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用 | |
| JP7791593B2 (ja) | 細胞透過性ペプチド変異体およびその用途 | |
| JPWO2021119756A5 (enExample) | ||
| JP2025532522A (ja) | 新規血小板由来増殖因子ペプチド模倣物 | |
| JP2004513059A (ja) | ペプチド産物、方法及び組成物 | |
| JP2025522281A (ja) | Cnp化合物の液体医薬製剤 |